Exact Science

[SnakeEYE]

Jack,i see gold starts fanning!How many clones,god damn it?!

 

[ammo]

Quote from soccerscott:

Trading is only a science after you have a large number of trades to put through analysis. At the end of the analysis, you will have a quantifiable set of numbers that states your success/failure.

However, like any statistical analysis, a single trade or small sub-group of trades can have a huge swing in probabilities and may not reflect the true mean average

The funny this is that I was discussing this with the traders in the office and we at first said this only applied to traders with a consistent strategy they did not deviate from. However, we realized that even a trader who was "shooting from the hip" would actually end up doing alot of the same things over and over again and end up with a quantifiable set up numbers that showed the true success/failure of the "system"

which would still be an average hypothesis based on a limited amount of data,deduced to an avg which would be avg,not exact

 

[nkhoi]

update, didn't sell when it hit 9

 

[pepdegree]

Quote from nkhoi:

update, didn't sell when it hit 9

Õàõààà..ïîçäðàâëÿþ ìîé äðóã!ïîòðàòü äåíüãè ñ óìîì!

 

[Albert Cibiades]

Surely there is a shitkicker bar near you that has a bull-ride machine. It is simultaneouslya buy and a sell.

 

[nkhoi]

I am out at 8.65, thank you stonedinvestor.

from seeking alpha;

10 Biotech Stocks Trading At The Deepest Discounts To Target Price
November 30, 2011 | includes: ACHN, ARIA, BCRX, EXAS, EXEL, HALO, NKTR, VRTX, XOMA, ZIOP

9. Exact Sciences Corporation (EXAS): Focuses on developing a molecular diagnostic screening technology for the early detection and prevention of colorectal pre-cancer and cancer. Market cap of $419.73M. Of the 11 analysts that have set a target price on the stock, the lowest price target stands at $9.00. This implies a current upside of 19.52% from current levels around $7.53. The stock is a short squeeze candidate, with a short float at 13.18% (equivalent to 11.06 days of average volume). The stock has gained 36.02% over the last year.

 

[stonedinvestor]

Out!

Well I guess you ought to go and get a full on colonoscopy then NK!

That's right the full probe is a thing of the past and this couldn't come fast enough as I'm approaching the 50 barrier.

Homey don't go there! Sorry. The EXAS COLOGUARD (snazzy name eh?) detects pre cancer cells almost 60% of the time purely from a butt wipe something we do every morning anyway.

Perhaps even more exciting is that COLOGUARD detects Stage 1 cancer 100% of the time...

There is a huge part of the medical industrial complex that wants this stock to fail!

There is that danger folks! Normally you take a ride like this you might get off and in fact I am thinking along similar lines but what of that break out point $9.80 we are close to that, could we just extend this through the 52 week high and crest out at $12.00? Hummmmm.

Maybe this could help- 07 Feb 20:00 EXACT Sciences Corp. at UBS Healthcare Services Conf.... ~stoney

 

[ocean5]

 

[ocean5]

òàêèå ìåëüêèå ëþäè íà ýòîì ñàéòå...äåä áû õîòü âûïîëç ÷òî ëè...

 

[Landis82]

Quote from stonedinvestor:

Out!

Well I guess you ought to go and get a full on colonoscopy then NK!

That's right the full probe is a thing of the past and this couldn't come fast enough as I'm approaching the 50 barrier.

Homey don't go there! Sorry. The EXAS COLOGUARD (snazzy name eh?) detects pre cancer cells almost 60% of the time purely from a butt wipe something we do every morning anyway.

Perhaps even more exciting is that COLOGUARD detects Stage 1 cancer 100% of the time...

There is a huge part of the medical industrial complex that wants this stock to fail!

There is that danger folks! Normally you take a ride like this you might get off and in fact I am thinking along similar lines but what of that break out point $9.80 we are close to that, could we just extend this through the 52 week high and crest out at $12.00? Hummmmm.

Maybe this could help- 07 Feb 20:00 EXACT Sciences Corp. at UBS Healthcare Services Conf.... ~stoney

Stoney, I've had a core investment in EXAS for over 5 years now. You can do a search and see some posts that I made on ET back in 2007 highlighting this Company.

The key is the new management team that came in about 3 years ago. CEO Kevin Conroy and CFO Maneesh Arora and Senior Research Scientist Graham LIdgard are Winners! At their last Company, "Third Wave Technologies" they developed an HPV screening test (Cervista) for cervical cancer. They sold the Company about a year before FDA approval to Hologic (HOLX) for $580 million in 2007.